Loading
HER2 Positive Breast Cancer / Triple Negative Breast Cancer / Breast Cancer · Interventional Study
ClinicalTrials.gov · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a clinical trial registry record describing a planned screening study of brain MRI in breast cancer patients across multiple subtypes. No results are posted; the study is active but not recruiting. The reader should note that this record documents intent and design only, not outcomes or efficacy.
Interventional, Randomized, Parallel, Open label, Screening purpose. Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Inflammatory Breast Cancer,…; age from 18 Years. Intervention: Inflammatory Breast Cancer Managed with Curative Intent; HR+ or HER2+ Metastatic Breast Cancer - Screening Arm; Triple Negative Breast Cancer. Compared with: HR+ or HER2+ Metastatic Breast Cancer - No Screening Arm — No Intervention. n = 214. 1 site: United States.
This is a clinical trial registry record describing a planned screening study of brain MRI in breast cancer patients across multiple subtypes. No results are posted; the study is active but not recruiting. The reader should note that this record documents intent and design only, not outcomes or efficacy.
Efficacy, safety, or clinical benefit cannot be assessed from a registry record without posted results.
The source did not state who this applies to in practice.
This is an active registry record for an ongoing interventional study with no results posted; it describes a planned screening intervention in breast cancer patients with primary outcomes focused on quality of life and incidence detection.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04030507). This is a study registration, not published results. Lead sponsor: Brigham and Women's Hospital. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 214 participants (ESTIMATED). Conditions: Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Inflammatory Breast Cancer, Metastatic Breast Cancer. Interventions: DEVICE: MRI. Primary outcome measures: Neurologic Quality of Life at 12 Months using the MD Anderson Symptom Inventory - Brain Tumor Module , 12 Months; Incidence of Symptomatic Brain Metastases , Through study completion, an average of 1 year; Incidence of Brain Metastases , Through study completion, an average of 1 year. Brief summary: This research study is studying the usefulness of magnetic resonance imaging (MRI) to screen for brain metastases (spread of the breast cancer to the brain).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.